Serina Therapeutics Secures $5M for Parkinson’s Treatment

Serina Therapeutics ( (SER) ) has provided an update.

On April 8, 2025, Serina Therapeutics announced a $5 million private placement of securities to support the development of SER-252, its lead candidate for advanced Parkinson’s disease. This funding will aid in initiating a Phase 1 clinical trial for SER-252, which uses Serina’s POZ technology to provide continuous dopaminergic stimulation, potentially offering significant benefits to patients.

Spark’s Take on SER Stock

According to Spark, TipRanks’ AI Analyst, SER is a Neutral.

Serina Therapeutics’ overall stock score is primarily hindered by severe financial challenges, including declining revenue, high liabilities, and negative cash flow. Although there is some short-term technical momentum, the valuation is weak due to negative earnings. Positive corporate developments and strategic initiatives are noted but do not offset the fundamental financial concerns.

To see Spark’s full report on SER stock, click here.

More about Serina Therapeutics

Serina Therapeutics is a clinical-stage biotechnology company focused on developing drug product candidates for neurological diseases and other indications. The company utilizes its proprietary POZ Platform™ technology to enhance drug efficacy and safety, with applications across small molecules, RNA-based therapeutics, and antibody-based drug conjugates. Serina is headquartered in Huntsville, Alabama.

YTD Price Performance: -2.16%

Average Trading Volume: 12,770

Technical Sentiment Signal: Strong Buy

Current Market Cap: $49.56M

See more data about SER stock on TipRanks’ Stock Analysis page.